We are international

The 2007 meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, Illinois in June, 2007. The IMF is pleased to bring you this webcast, which includes interviews with a number of the people who presented new findings of interest to the myeloma community.

ASCO 2007 Webcasts

Novel Agents
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota, USA
Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group.

Jean Luc Harousseau, MD
CHU Hotel Dieu
Nantes, France
Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone.

Pieter Sonneveld, MD
U. Hosp. Rotterdam
Dijkzigt, Netherlands
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma.

Keith Stewart, MD
Mayo Clinic
Scottsdale, Arizona, USA
Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses.

Stem Cell Transplantation
Bart Barlogie, MD, PhD
Arkansas Cancer Research Center
Little Rock, Arkansas, USA
Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma.

William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington, USA
Current status of stem cell transplantation: When? How Many? Allogeneic v Autologous or Both?

Joan Blade, MD
Central University
Barcelona, Spain
APETHEMA study of high-dose therapy/stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma

Syed T. Mahmood, MD
Mayo Clinic
Rochester, MN, USA
Outcome of patients relapsing early after autologous stem cell transplantation for multiple myeloma

Diagnostic Tests
Rachid Baz, MD
Cleveland Clinic
Cleveland, Ohio, USA
Prediction of response and progression in multiple myeloma (MM) with serum-free light chains (sFLC): Corroboration of the International Myeloma Working Group (IMWG) criteria.